U.S. Nasal Spray Market Size, Share & COVID-19 Impact Analysis, By Product Type (Corticosteroids, Salt Water Solutions, Topical Decongestants, Antihistamine, and Others), By Application (Nasal Allergies, Cold, Asthma, and Others), By Patient Type (Pediatric and Adults), By Type (Prescription and Over-the-Counter), By Distribution Channel (Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and Country Forecast, 2023-2030

The U.S. nasal spray market size was worth USD 10.32 billion in 2022 and is projected to grow at a CAGR of 8.8% during the forecast period. 

Nasal spray is used to relieve congestion and blockages in the nose. They are used for acute and chronic conditions and are available by prescription or over the counter. The growing prevalence of nasal disorders, such as chronic respiratory diseases is the key factor driving market growth. These medications provide targeted relief directly to the nasal passages by effectively relieving symptoms such as blockages, congestion, sneezing, and postnasal drip.

• For instance, according to the data published by the U.S. Department of Health and Human Services, respiratory diseases affect millions of people in the country. In contrast, around 25 million people in the U.S. have asthma. The organization focuses on increasing the prevention, detection, and treatment of respiratory disorders.

Furthermore, manufacturers in the market are heavily investing in R&D activities to develop new products to treat several chronic respiratory diseases. Such initiatives are estimated to create lucrative growth opportunities for the U.S. nasal spray market in the near future.

However, in 2020, the companies operating in the market witnessed a decline in their revenues from nasal spray products due to the COVID-19 pandemic. The market witnessed a negative impact due to the lesser occurrence of cold and flu diseases in this period as a result of social distancing.

U.S. Nasal Spray Market Trends

Growing Preference for Saline-based Nasal Sprays

Consumer preference for non-medicated and drug-free alternatives has led to the growing popularity of natural and saline-based products. These products contain ingredients such as a saline solution, herbal extracts, or aloe vera that reduce nasal congestion caused by allergies. Moreover, various new products containing natural ingredients have been launched in the market to treat allergies.

• For instance, in June 2020, GSK plc launched a PiriNatural saline nasal spray. The spray reduces nasal congestion caused by allergies by cleaning the nasal cavities with isotonic seawater and aloe vera.

U.S. Nasal Spray Market Growth Factors

Product Innovations and Launches to Drive Market Growth

Prominent players in the market are constantly exploring new formulations and delivery mechanisms to enhance the user experience and effectiveness of the nasal spray. The developments in muzzle designs, ensuring more controlled and precise spray patterns for better nasal coverage, along with the introduction of pump-based sprays, have made the products more environmentally friendly.

• For instance, in January 2023, AptarGroup, Inc., a global manufacturer of drug delivery systems, announced the launch of APF Futurity, a multidose, metal-free spray pump to deliver nasal saline and other comparable over-the-counter (OTC) formulations.

Such advancements attract consumers and boost competition among manufacturers, leading to a wider range of options available in the U.S. nasal spray market.

Request a Free sample to learn more about this report.

In 2021, the age group ranging from 20 to 24 years reported the highest percentage of asthma, with a total of 9.5%.

RESTRAINING FACTORS

Adverse Side-effects and Availability of Alternative Treatment Options May Hamper Market Growth 

The use of nasal sprays for a longer period can lead to bleeding from the nose and even headaches. In addition, incorrect use can cause nasal dryness, irritation, and rebound congestion. Moreover, the FDA has also claimed healthcare specialists should be conscious of the risk factors associated with these products. Furthermore, the availability of oral antihistamines such as Zyrtec, Allegra, and Claritin, along with saline rinses, can create a challenge to the U.S. nasal spray market growth.

U.S. Nasal Spray Market Segmentation Analysis

By Product Type Analysis

Based on product type, the market is classified into corticosteroids, salt water solutions, topical decongestants, antihistamine, and others.

In 2022, the corticosteroids segment accounted for the largest U.S. nasal spray market share owing to the growing prevalence of nasal allergies and new product launches in the market. This is further augmented by the growing mergers and acquisitions among market players aiming to consolidate their position in the market.

• For instance, in May 2023, Indivior PLC received the U.S. FDA approval for its prescription Opvee nasal spray. The product is easy to use and reverses overdoses affected by fentanyl and other opioids.

Furthermore, the salt water solutions segment is projected to grow at the fastest-growing CAGR during the forecast period due to the increasing consumer preference for non-medicated and drug-free alternatives.

By Application Analysis

Based on application, the market is segmented into nasal allergies, cold, asthma, and others.

The nasal allergies segment dominated the market in 2022. The prominent factor driving the segmental growth is the growing population suffering from respiratory conditions leading to nasal allergies. Moreover, new product approvals from the U.S. FDA and product launches are projected to drive segmental growth in the upcoming years.

The asthma segment is anticipated to expand at the highest growth rate during the forecast period, 2023-2030. The segmental growth is due to the growing rates of respiratory diseases coupled with the demand for economical treatment options. Moreover, growth in the funding from private and government organizations for the development of research centers and advancement in R&D activities in the healthcare division are other factors influencing the segmental growth.

By Patient Type Analysis

In terms of patient type, the market is segmented into pediatric and adults.

The adults segment accounted for the largest market share in 2022, owing to the growing number of adult patients suffering from asthma and COPD. For instance, according to data published by the CDC, among total asthmatic patients, around 81.3% are aged above 18 years.

The pediatric segment is projected to grow at the highest CAGR during the forecast period owing to the growing use of the product for the treatment of chronic respiratory diseases in pediatrics. Furthermore, the rising number of government initiatives and programs for infectious disease awareness in pediatric are projected to boost the adoption of these products.

By Type Analysis

On the basis of type, the market is segmented into prescription and over-the-counter.

The prescription segment accounted for the dominant share of the market in 2022. The growing R&D investments for novel drugs and the increasing number of launches of generic equivalents by various manufacturers are projected to drive segmental growth in the near future. Some of the prescription-based drugs available in the market are azelastine (Astelin, Astepro) and olopatadine (Patanase).

The over-the-counter segment is expected to expand at the fastest-growing rate over the forecast period. The growth in the sales of online and private-label OTC products is projected to boost the segmental growth.

By Distribution Channel Analysis

Based on distribution channel, the market is segmented into drug stores & retail pharmacies, hospital pharmacies, and online pharmacies.

The drug stores & retail pharmacies segment dominated the market in 2022. The growth was mainly attributed to the availability of diverse product choices and the presence of skilled pharmacists.

On the other hand, the online pharmacies segment is projected to grow at a highest CAGR from 2023-2030, owing to the increase in telecommunication and diagnostic support.

An Infographic Representation of U.S. Nasal Spray Market

View Full Infographic

To get information on various segments, share your queries with us

List of Key Companies in U.S. Nasal Spray Market

The U.S. nasal spray market is highly competitive with some of the leading players, including GSK Plc, Johnson & Johnson Services, Inc., Emergent Devices, Inc., Viatris Inc., and Bayer AG. The strong product portfolio of these companies and the emphasis on launching advanced products in the market are factors responsible for their dominant share.

• For instance, in June 2021, Bayer announced that the U.S. FDA has approved over-the-counter sales of Astepro Allergy as an (OTC) product for temporary relief from sneezing, runny nose, nasal congestion, and itchy nose.

Furthermore, other manufacturers such as Assertio Therapeutics, Inc., Cipla, Inc., AptarGroup, Inc., Oyster Point Pharma, Inc., the Procter & Gamble Company, and many more are striving to launch unique features such as long-lasting effects, faster relief, or improved user experience.

LIST OF KEY COMPANIES PROFILED:

• GSK plc (U.K.)


• Viatris Inc. (U.S.)


• Emergent Devices, Inc. (U.S.)


• Cipla, Inc. (India)


• Bayer AG (Germany)


• Aurena Laboratories (Sweden)


• Aytu Health (Innovus Pharmaceutical) (U.S.)


• The Procter & Gamble Company (U.S.)


• AstraZeneca (U.K.)


• Johnson & Johnson Services, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• August 2023: Emergent BioSolutions Inc. announced over-the-counter access for its NARCAN Naloxone HCl 4 mg nasal spray to treat opioid overdose.


• August 2021: Hikma Pharmaceuticals PLC, the global pharmaceutical company, announced the launch of KLOXXADO (naloxone HCl) nasal spray 8mg in the U.S. for the emergency treatment of opioid overdose for adult and pediatric patients.


• August 2020: Janssen Pharmaceutical Companies of Johnson & Johnson announced that its nasal spray product SPRAVATO (esketamine) received the U.S. FDA approval to treat depressive symptoms in adults.

REPORT COVERAGE

The U.S. nasal spray market forecast provides a detailed analysis of the market. It focuses on key aspects such as the prevalence of chronic respiratory diseases and new product launches. In addition, it includes critical industry developments such as mergers, partnerships, acquisitions and the impact of COVID-19 on the market. Besides this, the research report also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market over recent years.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation